Should MRI be used to determine the duration of treatment in spinal tuberculosis?

McGhee, Emily; Chengappa, Kolera; Breen, Ronan; Lucas, Jonathan; Milburn, Heather

doi:10.1183/13993003.congress-2015.pa3342

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study by C oronel et al [ 88 ] using AERONOSE suggested there might be changes in exhaled breath in the first 2 months of treatment. The use of magnetic resonance imaging for spinal tuberculosis was advocated by M c G hee et al [ 89 ] but the audience agreed that distinguishing bacterial cure from continuing inflammatory responses and bone remodelling made the use of such an expensive test impractical, especially in the absence of evidence from a randomised controlled trial. Whether there might be strain-related problems with treatment success and relapse was considered by H ang et al [ 90 ] but discounted in the absence of clinical data regarding adherence and other patient-related variables.…”

Section: Tuberculosismentioning

confidence: 99%

The best of respiratory infections from the 2015 European Respiratory Society International Congress

Polverino

Bothamley

Goletti³

et al. 2016

ERJ Open Res

View full text Add to dashboard Cite

The breadth and quality of scientific presentations on clinical and translational research into respiratory infections at the 2015 European Respiratory Society (ERS) International Congress in Amsterdam, the Netherlands, establishes this area as one of the leadings fields in pulmonology. The host–pathogen relationship in chronic obstructive pulmonary disease, and the impact of comorbidities and chronic treatment on clinical outcomes in patients with pneumonia were studied. Various communications were dedicated to bronchiectasis and, in particular, to different prognostic and clinical aspects of this disease, including chronic infection with Pseudomonas and inhaled antibiotic therapy. Recent data from the World Health Organization showed that Europe has the highest number of multidrug-resistant tuberculosis cases and the poorest countries have the least access to suitable treatments. Latent tuberculosis and different screening programmes were also discussed with particular attention to risk factors such as HIV infection and diabetes. Several biomarkers were proposed to distinguish between active tuberculosis and latent infection. Major treatment trials were discussed (REMOX, RIFQUIN and STREAM). The possibility of once-weekly treatment in the continuation phase (RIAQUIN) was especially exciting. The continuing rise of Mycobacterium abscessus as a significant pathogen was noted. This article reviews some of the best contributions from the Respiratory Infections Assembly to the 2015 ERS International Congress.

show abstract

Section: Tuberculosismentioning

confidence: 99%